Hangzhou Nain Biotechnology

Hangzhou Nain Biotechnology is a Chinese biopharmaceutical company specializing in the discovery and development of nanobody-based therapeutics. The company utilizes a proprietary VHH antibody platform that integrates camelid immunization, phage display library construction, and high-throughput screening to generate high-affinity single-domain antibodies. These nanobodies are designed to overcome the limitations of conventional antibodies, offering enhanced tissue penetration, stability, and the ability to form multi-specific constructs. Nain Biotech's research and development efforts primarily focus on oncology and immunology, with a pipeline of candidates currently in pre-clinical evaluation. The company also provides specialized technical services related to nanobody engineering and production for academic and industrial partners.